US Patent Issued to Beijing Giluntide Pharmaceutical on July 15 for "Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy" (Chinese Inventors)

Posted On: 2025-07-16

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,357,712, issued on July 15, was assigned to Beijing Giluntide Pharmaceutical Co. Ltd. (Beijing).

"Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy" was invented by Fan Wang (Beijing), Jiyun Shi (Beijing), Hannan Gao (Beijing) and Bing Jia (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "A pharmacological composition contains a complex having a structurally modified RGD polypeptide a radionuclide. This pharmacological composition is useful for diagnosis or treatment of the integrin AlphavBeta3-positive tumors. The pharmacological composition may further contain ...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

US Patent Issued to Beijing Giluntide Pharmaceutical on July 15 for "Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy" (Chinese Inventors)